Recent Posts

  • Cel-Sci Corp (CVM): The Trial Is Over And Shares Are Setting Up For Results. Boom or Bust?

    May 12, 2020

    Disclaimer:  VFC has no affiliation with Cel-Sci Corp or with any third parties associated with the companies.  VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog.  VFC does not offer advice or investment services and nothing you read here should be construed as such.  VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table.  #AhYeah.

    Shares of Cel-Sci Corp (CVM) are hot and in the spotlight these days after the company announced last week that the last "event," or death, necessary to complete data analysis for its global Phase III trial testing Multikine in the treatment of head and neck cancer had occurred.  After nearly a decade of waiting through many peaks and valleys of trading for CVM, investors were elated that the trial results are finally on their way.  There is much speculation, however, as to just how long the wait for analysis will take.  

    According to the press release, "The database is now being prepared for database lock. Once the database has been locked the final analysis of the trial results can be performed."  write up by Zachs a few days ago does a pretty good job of outlining which steps may take place between the last event and data release.  A few of those steps could take a little bit of time, especially in the middle of this Covid19 pandemic that we are experiencing.  Zachs also mentioned the possibility of the data being discussed at an upcoming conference later this year...

    Click 'Read more' below to read more.  First, use the link below for discounts to great backpacks and travel supplies!

    Use this link for some awesome travel backpacks and supplies!  Using the code READYPROAF15 will get you a 15% discount at checkout!  Ah yeah!

  • Titan Pharmaceuticals (TTNP): Off To The Races With Earnings Due

    May 06, 2020

    Disclaimer:  VFC has no affiliation with Titan Pharmaceuticals or with any third parties associated with the companies.  VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog.  VFC does not offer advice or investment services and nothing you read here should be construed as such.  VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table.  #AhYeah.

    Shares of Titan Pharmaceuticals (TTNP) jumped by over twenty percent on Tuesday with volume nearly four times the daily norm.  After hours action brought another three percent rise in the price, bringing the daily gain to about twenty five percent.  Not bad for this stock that has been heavily beaten down since reaching highs of over two dollars last year.  

    discussed this stock a on a couple of occasions last month when it became apparent that it was a good company to keep an eye on leading into the upcoming earnings report and it looks like some past event and future catalysts have drawn additional eyes onto Titan - it has also attracted the eyes of the swing, momentum and day traders, which means there will be plenty of volatility along with any upwards trend that may materialize.

    Titan is a very speculative small cap company - market cap is still under thirty million even after yesterday's spike - but has a solid foundation of an approved product which treats a huge need in today's global environment.  That product is Probuphine.  

    Click 'Read more' below to jump to the full blog post! Buy a plane ticket first, tho.  This lockdown won't last forever.

    Fly Now, Pay Later. Easy monthly payments over 3, 6, or 12 months.

     

     

  • Hot Stock to Watch: Titan Pharmaceuticals (TTNP): Well Positioned For A Rebound!

    Apr 27, 2020

    Disclaimer:  VFC has no affiliation with Titan Pharmaceuticals or with any third parties associated with the companies.  VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog.  VFC does not offer advice or investment services and nothing you read here should be construed as such.  VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table.  #AhYeah.

    Shares of Titan Pharmaceuticals (TTNP) are also worth watching this week.  

    Titan is the proprietary owner and distributor of Probuphine, an implant a slow-releasing buprenorphine implant based on the company's ProNeura technology to treat opioid addiction.

    Opioid addiction is a scourge of global society, helmed by not only the cartels and criminals, but by the biggest drug-pushers in the world - the pharmaceutical industry.  The amount of people dying from drug overdose rivals what we've seen from Covid19, but with less the fanfare.  Titan pharmaceuticals is in a prime position to take advantage of some of the treatment market share, especially since the Probuphine implant is slow-releasing and alleviates the threat of overdose.

    Click 'Read more' below the ad to continue!  Great travel deals and discount codes with the link below!  Get ready for that post-covid travel!

    Use this link for some awesome travel equipment!  Using the code READYPROAF15 will get you a 15% discount at checkout!  Ah yeah!

  • Hot Stock to Watch: CVM Friday Spike Brings Volume and Price Momentum As Trial Results Loom

    Apr 27, 2020

    Disclaimer:  VFC has no affiliation with Cel-Sci Corp or with any third parties associated with the companies.  VFC has received no compensation for this blog post, although there may be an unrelated advertisement or two at various locations on this blog.  VFC does not offer advice or investment services and nothing you read here should be construed as such.  VFC is just a guy with an opinion and access to a computer and a keyboard; bringing discussion and ideas to the table.  #AhYeah.

    If you haven't been paying attention to Cel-Sci Corp (CVM) yet, you might want to pay attention now.  We've discussed CVM many times on this blog over the course of the past decade as the company has taken its lead product candidate, Multikine, from successful Phase II trials through what is thought to be the largest head and neck cancer trial ever undertaken.  

    Shares trades over two dollars higher (a nearly 20% price spike) on higher-than-normal volume on Friday, making it a stock to watch during the coming week.

    If you are new to the CVM stock, take a read of the next couple of paragraphs for a quick catch-up on the Multikine story, as discussed in previous blog posts on VFC's Stock House.  If you're already caught up, skip the italics.

    Why the interest?  

    Cel-Sci is in the late stages of a robust Phase III trial testing Multikine, the company's lead developmental product, for the treatment of head and neck cancer.  Multikine is one of the newer breed of cancer immunotherapy treatments, which are designed to harness the body's own immune system to fight and possibly defeat cancer cells.  What is unique about Multikine, tho, is that the treatment is administered before the Standard of Care (SOC) treatment. 

    Why is this significant? Click "Read more" below the ad (great airline deals, by the way) to continue!

    Airfares are cheap these days, plan for that post-lockdown vacation now!  Put those stock winnings to good use!Travel, see the world and get some great airfare deals!

    Fly Now, Pay Later. Easy monthly payments over 3, 6, or 12 months.

  • Some of VFC's Mental Notes And A Couple Of Quarantine Stock Picks - #StayHome

    Apr 01, 2020

    Regardless of whether you believe in "Medicare for All" or not, the Covid19crisis has let us know we need something.  The first world health care systems - public, private, and the socialized systems of Europe - were all woefully unprepared for this fight.  

    The amount of money spent on producing and stockpiling weapons of war - missiles, tanks, land mines, rifles, grenades, you name it - and there's always more if needed; yet the stockpiles of weapons of life to arm our Doctors, Nurses and healthcare workers was simply just not there.  Priorities much, Governments of the World?
    A lot of people with a lot of money have it pretty good - not just because they have a lot of money; but because the ignorance of living in a bubble keeps them out of touch from the real world where pain, fear, and suffering is felt every day.  Sending your kids to Spring Break in the middle of a growing pandemic?  Must be nice to be so oblivious to the world around you.
    Click 'Read more' below for more...

  • COVID-19, We Gotta Take This Thing Seriously

    Apr 01, 2020

    This one isn't about stocks, or investing, or making money.  That can all wait for now.  What we need to do now is take this #COVID19 seriously.
    If you’re still on the fence of taking this thing seriously or not, ya gotta get off the fence and take it seriously. Yes, some - in fact, most - fight off the virus fairly easily.  But many don’t.  Reading the press from around the world, there are everyday people of all ages succumbing to this virus, not just the elderly and those pre-stricken with other health conditions.  Everyone is at risk.  You don’t know who’s life you can be putting in danger by going about your routine business day in and day out. This is serious, treat it that way.
    Continued with the link below....

  • Cel-Sci Corp (CVM) Collaboration Announced LEAPS for Coronavirus (COVID-19), Shares Trade Higher

    Mar 23, 2020

    Earlier today I posted a write-up on my blog regarding Cel-Sci Corp (CVM) and the company's potential for Multikine, a potential billion-dollar blockbuster if proven successful in a Phase III head and neck cancer trial for which we may see imminent results.  I also discussed Cel-Sci's LEAPS platform, an immunotherapy treatment that had been looked at previously to treat the H1N1 flu years ago.  If you haven't checked out that blog post already, you might as well now.  It's a decent read.

    Click the Read More link below to a follow-up post regarding today's news about LEAPS for the potential treatment of Coronavirus and how it will / could / should affect the CVM share price moving forward.

    Ah yeah.

    Airfares are cheap these days, plan for that post-lockdown vacation now!  Put those stock winnings to good use!Travel, see the world and get some great airfare deals!

    Fly Now, Pay Later. Easy monthly payments over 3, 6, or 12 months.

  • Stock Market Dip Picks: Cel-Sci (CVM) Multikine Results Could Be Imminent!

    Mar 23, 2020

    Stay safe, stay home - don't spread the virus.  Although you may be young and strong, those at the highest risk of contracting the virus don't appreciate those who are not taking it serious.  It could be your grandparents who you infect - or someone else's.  We're all in this together.  Take it seriously.

    While quarantined at home, let's continue to take a look at some stocks that can rebound when the madness is over and Thanos retreats...

    Use this link to buy excellent quality travel supplies! https://lddy.no/bzhc

    Cel-Sci Corp (CVM) isn't one that snuck up on us, we've been chatting about it for a while now due to the potential of the company's possibly ground-breaking cancer immunotherapy treatment, Multikine .  
    CVM is also not necessarily a 'stock market crash pick' either, because although shares have retreated off their recent highs of over $17 when the market fell, they've rebounded nicely and are hovering right around the twelve dollar price.  Given how much short interest this stock has held combined with childish attempts to drive the share price lower (see recent PR about an "investigation" by a law firm to find "possible" breaches of fiduciary duty), and shares are looking pretty good about now, given the overall market turmoil....
    Click below to Read More!!!

  • Stock Market Dip Stocks: Zosano Pharma (ZSAN) A Rebound and an FDA Play.

    Mar 18, 2020

    Use this link to buy excellent quality travel supplies! https://lddy.no/bzhc

    It's a crazy world right now, hopefully everyone is taking Covid-19 serious enough to exercise risk management in regards to spreading it around - our elderly and compromised are most at risk, so be smart and don't take it lightly how easily this thing spreads.  It's not just about you, your actions could affect others; we are all in this together.

    That said, a by-product of the virus is a monumental drop in a whole lotta share prices in the stock market.  This could turn into an opportunity for opportune traders not seen since the crash of 2008/2009 when some incredible gems were thrown our way.  A few off the top of my head I can recall were Citi (C) for about a buck, Microsoft (MSFT) for twenty one bucks, SiriusXM (SIRI) traded for mere pennies at one point, and Google (GOOG), or Alphabet however you want to call it, dropped again down into the three hundred dollar range.  Point being, there were plenty of gems that recovered from that crash, although a few that didn't.  Those that were not afraid of the red in the market and jumped in while others were selling ended up making bank. 

    That may be the case once again.  While things look bleak, the markets will persevere. 

    They will rebound.

    One of the stock stories I'm following right now is:

    Zosano Pharma (ZSAN):  Love this one for under fifty cents.

    Use this link to buy excellent quality travel supplies! https://lddy.no/bzhc

  • Cel-Sci (CVM) Slammed - What's Next?

    Feb 27, 2020

    Shares of Cel-Sci (CVM) were trimmed by a third on Wednesday, closing the day at just under eleven bucks after hitting as low as $6.35 at one point.  The only "news" to hit the wires during the blood bath was a Letter to Shareholders issued by CEO Geert Kersten, which pretty much retells the Multikine story from its infancy to where it stands today.  For those that my just be tuning in as a result of the Wednesday massacre, Multikine is Cel-Sci's Phase III immunotherapy treatment for head and neck cancer.  Multikine harnesses the body's immune system to combat the cancer cells and is unique because it is applied before the Standard of Care treatment while a patient's immune system is still strong. The Phase III trial was expected to end long end, but it has not yet ended, leaving many to speculate that the treatment must be working.  The event that will end the trial is the 298 death mark, a number that many speculate will be reached this month or shortly thereafter.

    Given the company's somewhat bumpy history - combined with the general volatility of the sector - CVM has attracted quite the interest of shorts, generally keeping a pretty good lid on any previous price runs.  That said, the shorts have failed at keeping a lid on the CVM price run as it jumped from under three dollars to as high as nearly eighteen dollars in the past year, even as them shorts were attempting to tell people to sell every step of the way.  To put this stock's price run over the past year into perspective, consider that the closing price after Wednesday's price smash, it is still more than a triple from where it opened last year.

    So why the drop?

    Click below to read more and find out!

    Use this link to buy excellent quality travel supplies! https://lddy.no/bzhc

  • Cel-Sci Corp (CVM): The Endgame is Closing, It's Game Time Now

    Sep 26, 2019

    Shares of Cel-Sci Corp (CVM) had a very solid trading day on Wednesday, trading up by over five percent on volume that was nearly double the recent daily trading average - aside from a couple of days of high volume that pushed the price through nine bucks in mid-September.  For recent followers of my blog, I've been pointing out the potential catalysts for this company since early this year.  For those who have been following for a while, you'll know I've been tracking CVM since prior to the commencement of the Phase III trial and have traded in and out over the years.

    As with every developing biotech, Cel-Sci has experienced many peaks and valleys during the process of bringing Multikine, the company's lead product candidate for the treatment (or cure, as stated in the company's investor presentation) of head and neck cancer.  Although many on the short side of the biotech sector will use these peaks and valleys to incite fear into the less battle-hardened investors, the volatility is absolutely normal during the process and is no indication of the final success or failure of a drug or treatment.  "Biotech" is a trading sector in the broad markets and it is not run by science; the scientists run the science in the labs and - for the most part - steer clear of navigating the trading sector.

    Click Read More below to read more...

  • Cel-Sci Should Be On Your Speculative Radar, With Potential Catalysts Pending

    Sep 04, 2019

    As previously discussed, Cel-Sci is in the final stages of a global Phase III trial testing the effectiveness of its lead product candidate, Multikine, in the treatment of head and neck cancer.  You can click HERE for my previous blog posts on the subject or scroll down the home page, if you'd like.  Although the share price and trading volume has somewhat stagnated through the summer months - as short interest continued to increase - a few items of interest are coming up that could reinvigorate life into CVM trading action...

    Click "Read more" below to read more!

» Visit articles